Literature DB >> 20109615

Transplant outcomes for primary immunodeficiency disease.

Angela R Smith1, Thomas G Gross, K Scott Baker.   

Abstract

Primary immune deficiencies (PIDs) are rare diseases, and most are lethal without appropriate intervention. Hematopoietic cell transplantation (HCT) can cure the majority of patients, but most lack a suitable matched related donor. Alternative donor stem cells (mismatched related donor bone marrow, unrelated donor bone marrow, and unrelated donor umbilical cord blood [UCB]) are therefore frequently required. Published data comparing outcomes after alternative donor transplant for PID are scarce. The outcomes and potential advantage and disadvantages of each alternative stem cell source are discussed in this chapter. Although there are insufficient prospective data to make meaningful comparisons between the alternative stem cell sources, the results presented here demonstrate clearly that the use of UCB transplantation for PID is a viable option and may be advantageous in many situations. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20109615     DOI: 10.1053/j.seminhematol.2009.10.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  5 in total

1.  Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

2.  Use of TCR α+β+/CD19+-Depleted Haploidentical Hematopoietic Stem Cell Transplant Is a Viable Option in Patients With Primary Immune Deficiency Without Matched Sibling Donor.

Authors:  Tim Brettig; Joanne Smart; Sharon Choo; Francoise Mechinaud; Richard Mitchell; Trisha Soosay Raj; Theresa Cole
Journal:  J Clin Immunol       Date:  2019-06-06       Impact factor: 8.317

3.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.

Authors:  W P Miller; R Shanley; P Dorostkar
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

4.  Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.

Authors:  Niek P van Til; Helen de Boer; Nomusa Mashamba; Agnieszka Wabik; Marshall Huston; Trudi P Visser; Elena Fontana; Pietro Luigi Poliani; Barbara Cassani; Fang Zhang; Adrian J Thrasher; Anna Villa; Gerard Wagemaker
Journal:  Mol Ther       Date:  2012-06-12       Impact factor: 11.454

5.  Impact of maternal and neonatal factors on parameters of hematopoietic potential in umbilical cord blood.

Authors:  Sara Y Al-Deghaither
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.